Jennifer L. Taubert - Feb 12, 2024 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, WWC. Innovative Medicine
Signature
/s/ Raavi K. Deol, as attorney-in-fact for Jennifer Taubert
Stock symbol
JNJ
Transactions as of
Feb 12, 2024
Transactions value $
-$2,109,632
Form type
4
Date filed
2/14/2024, 06:36 PM
Previous filing
Feb 12, 2024
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +22.4K +15.86% $0.00 164K Feb 12, 2024 Direct F1
transaction JNJ Common Stock Options Exercise $0 +3.77K +2.3% $0.00 168K Feb 12, 2024 Direct F2
transaction JNJ Common Stock Tax liability -$2.11M -13.4K -8% $157.40 154K Feb 12, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Performance Share Units Options Exercise $0 -22.4K -100% $0.00* 0 Feb 12, 2024 Common Stock 22.4K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Awarded under Issuer's Long-Term Incentive Plan. Performance Share Units awarded on February 8, 2021; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board on February 12, 2024.
F2 Shares earned due to performance factor of 116.8% upon certification of performance results by the Board.
F3 Shares withheld for payment of taxes upon vesting of Performance Share Units and certification of performance results by the Board.